November 2024
The global in vitro diagnostics market was estimated at US$ 77.95 billion in 2023 and is projected to grow to US$ 123.45 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.45% from 2024 to 2034. With the growing number of people and various diseases, the need for in vitro diagnostics has grown, and it is expected that the demand for in vitro diagnostics will continue in the future as well.
Unlock Infinite Advantages: Subscribe to Annual Membership
According to the World Health Organization, in vitro diagnostics (IVDs) are different types of tests conducted for the detection of infections, diseases, and conditions. IVDs are conducted using glass equipment in the laboratory, which is completely different from in vivo tests, which are conducted in the body itself. The in vitro diagnostics market is involved in the production of kits & reagents, biological material, equipment, and other resources needed for conducting tests. Various other aspects associated with IVD, such as conducting evidence-based research, clinical trials, gathering data, etc, are also part of the market. The growing prevalence of various diseases and the need to control the spread of the disease increases the demand for in vitro diagnosis.
AI and machine learning have become an essential part of the healthcare industry. Smart diagnostics has become a thing due to the integration of AI in IVDs. AI plays a significant role in clinical decision-making because healthcare professionals can rely on the judgment made by AI algorithms. AI and machine learning have been integrated into various diagnostic equipment, software, and applications. This addition helps in analyzing large data, providing accurate results, reducing time & cost, conducting predictive analysis, decision-making, and much more. With the growing burden of healthcare professionals and resources, AI can be highly useful in managing resources, efforts, and time, which can lead to cost savings and staff satisfaction.
For instance,
| Company Name | F. Hoffmann-La Roche Ltd. |
| Headquarters | Basel, Switzerland, Europe |
| Recent Development | In September 2024, with the addition of over 20 cutting-edge artificial intelligence (AI) algorithms from eight new partners, Roche announced the expansion of its digital pathology open environment. Using state-of-the-art AI technology, these strategic partnerships seek to assist scientists and pathologists in the study and detection of cancer. |
| Company Name | Siemens Healthineers AG |
| Headquarters | Erlangen, Germany, Europe |
| Contribution |
The company is a global provider of various healthcare products, including diagnostic products and services. In the year 2023, the company’s diagnostics segment revenue was € 36 billion. In August 2023, Medical Physics Holdings, LLC's membership interest was fully bought by Siemens Healthineers. Cash payments of US$94 million (€85 million at the time of acquisition) were made for the transaction. Separate from the sale, Siemens Healthineers redeemed Aspekt Solutions' financial obligations, which totaled US$ 12 million (€11 million at the time of acquisition). |
The United Nations developed 17 sustainable development goals (SDGs), which focus on the sustainable development of different fields. Among the 17 SDGs, SDG 3 is ‘Good Health and Well-Being,’ which significantly helps in the growth of the market. One of the targets of SDG 3 is reducing the cases of tuberculosis, AIDS, and malaria, combatting hepatitis and neglected tropical diseases, and combating water-borne diseases and other communicable diseases. This goal significantly requires in vitro diagnostics resources and tools. Another component of the goal is to promote R&D on medicines and vaccines for communicable and non-communicable diseases.
Technological advancements have improved IVDs. Now, it is possible to get accurate results in less time. However, this has also become a restraining factor for the growth of the in vitro diagnostics market because these advanced diagnostics are expensive, and a lot of people cannot afford them, especially those who belong to the lower and middle classes. In countries where even basic healthcare facilities are not available, advanced diagnostic resources are not accessible. Apart from this, even in developed countries, it becomes difficult to provide these resources in rural and remote areas.
A lot of efforts have been made to grow the in vitro diagnostics market in recent years. Point of care holds great potential for improving IVDs. Point-of-care testing (POCT) means conducting a diagnosis wherever the patient is located. This allows the market players to visit people in remote locations to provide different diagnostic services. Currently, there are various tests and devices available for POCT, and in the future, there is scope for developing highly sensitive, rapid, and low-cost tests.
For instance,
By product, the reagents segment dominated the in vitro diagnostics market in 2023 and is expected to remain dominant in the predicted time frame. This segment consists of raw materials, kits, solutions, enzymes, primers, antigens, antibodies, buffers, and other components that are needed for conducting tests. These components come in the form of kits or sold individually based on their needs and demand. The reagents are clinically approved and undergo rigorous monitoring and quality control, which ensure that the end products are of top quality and provide accurate results when used. Reagents are the most important part of IVDs, and hence, this segment is growing rapidly.
For instance,
By technology, the immunoassay segment held the largest share of the in vitro diagnostics market in 2023. It is estimated that more than 100 million immunoassay tests are conducted every year. Immunoassays are widely used in various important areas of pharmaceutical analysis for disease diagnosis, therapeutic drug monitoring, and drug discovery. Immunoassays have high throughput, high sensitivity, and inherent specificity. Immunoassays are used in in monitoring allergic agents, infectious diseases, proteins, hormones, antibodies, TDM, and drug abuse.
For instance,
The infographic represents the total cases of infectious diseases along with the prevalence of different infectious diseases. From the graph, it can predicted that the major contributors to the growth of the in vitro diagnostics market are malaria, HIV/AIDS, TB, diarrhea, typhoid, and hepatitis.
By application, the infectious diseases segment held the largest share of the in vitro diagnostics market in 2023. Infectious diseases are contagious and, hence, require continuous diagnosis. The COVID-19 pandemic is one of the biggest examples of infectious diseases and the importance of diagnosis. In vitro diagnostics is an essential component of controlling the spread of infectious diseases, as they can be life-threatening if not treated on time. Timely diagnosis also prevents its spread and reduces the burden of healthcare costs. According to the World Health Organization, lower respiratory infections are the 5th leading cause of death, and tuberculosis is the 10th leading cause of death globally.
By end-use, the hospitals segment was dominant in the in vitro diagnostics market in 2023. With a large number of patient visits, the segment dominates in IVDs. On a daily basis, various IVD tests are run to diagnose diseases and monitor patients' health. Hospitals have their own laboratories for conducting tests and are equipped with advanced technologies. Patients prefer listing hospitals due to the advanced infrastructure and availability of healthcare professionals for different needs. Many patients, especially elderly patients who need continuous monitoring, are obligated to visit and stay in hospitals, which increases the demand for hospitals.
By region, North America dominated the in vitro diagnostics market share by 43% in 2023. The growth of the market in North America is attributed to the advanced healthcare system. The hospitals, clinical laboratories, and other healthcare infrastructure are equipped with advanced equipment and diagnostics resources. Another factor that contributes to the growth of the market in this region is the presence of key market players that contribute to developing new products and services in IVDs. North America also holds the largest share of the pharmaceutical and biotechnology industries, which significantly contributes to IVDs. The U.S., Canada, and Mexico are the major contributors in the revenue generation.
The U.S. held the dominant share of the in vitro diagnostics market in the North American region due to advanced infrastructure, highly qualified healthcare professionals, and growing awareness about IVDs. In 2022, the spending on the U.S. healthcare system increased by 4.1%, which was equivalent to US$ 4.5 trillion or US$ 13,493 per person. Another factor that contributes to the dominance is the growing prevalence of various chronic communicable and non-communicable diseases. Some of the major health issues that need IVD are tuberculosis (8331 cases in 2023), chronic lower respiratory disease (More than 35 million people live with this condition), and cancer (1,958,310 new cancer cases in 2023).
Canada is also among the countries with an advanced healthcare system. The Government of Canada constantly makes efforts to develop the healthcare infrastructure. For instance, to strengthen public healthcare for over ten years, the government invested US$ 200 billion. To tackle supply shortages of medical devices and essential drugs, the government also invested US$ 3.2 million.
Asia Pacific’s Growth Due to Growing Prevalence of Diseases
By region, Asia Pacific is expected to grow at a significant rate during the forecast period. The growing prevalence of diseases is driving the in vitro diagnostics market. Lack of education, lack of healthcare services in rural areas, and growing population contribute to the growing number of diseases in Asia Pacific. The governments in Asia Pacific are continuously making efforts to tackle this challenge. The market is also growing because many market players are taking initiatives to provide resources that will improve the healthcare systems, especially in underdeveloped and developing countries.
India is contributing to the growth of the in vitro diagnostics market due to the growing prevalence of diseases. There is a growing number of infectious diseases and chronic conditions in the country. The Government of India is taking various initiatives to tackle the challenges. Of the initiatives is the Infectious Disease Biology Program, which aims to provide solutions to various diseases, including vector-borne diseases, HIV/AIDS, and tuberculosis. The healthcare budget for 2024-2025 also indicated the seriousness of addressing health issues in India. The budget for 2024-2025 was Rs. 90,958.63 crore, which is 12.9% more than the healthcare budget for 2023-2024, which was Rs. 87,656.90 crore.
For instance,
By Product
By Technology
By Application
By End-use
By Region
November 2024
November 2024
November 2024
November 2024
Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts